CenTNF hits end point

Centocor Inc. on Friday announced positive results of its Phase III study of its CenTNF anti-TNF monoclonal antibody in a subpopulation of patients with Crohn's disease, a chronic inflammatory disease of the gastrointestinal tract.

Based on the results, CNTO (Malvern, Penn.) said it anticipates filing an BLA by the end of the year

Read the full 522 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE